The overarching goal of this program of research is to reduce smoking-related health disparities by increasing smoking cessation among Black adults. The goal of this research proposal is to determine whether more intensive, culturally specific, evidence-based interventions are more effective at promoting long-term cessation and other key patient-centered outcomes compared to the usual evidence-based standard of care: services provided by a state-run quitline. This study compares the relative effectiveness of three different treatments (Standard, Intensive, and Intensive Incentivized) on long-term smoking cessation (biochemically confirmed abstinence from combusted tobacco at 26-weeks post-target quit day) among Black adults who smoke and want to quit.

Start Date01 Jun 2026

Sponsor / Collaborator

University of Wisconsin-Madison

[+1]

NCT07398976

/ Not yet recruitingNot ApplicableIIT

Sex Differences in E-Cigarette Perception: Study 2

This study examines differences between males and females in the appeal and addiction potential of menthol flavored e-cigarettes with and without nicotine.

Start Date01 Apr 2026

Sponsor / Collaborator

Yale University

[+1]

NCT06334016

/ Not yet recruitingEarly Phase 1IIT

Acute Effects of Sequential Nicotine Vaping on the Pharmacokinetic and Pharmacodynamic Properties of Vaped THC: A Double-Blind, Placebo-Controlled, Randomized Within-Subject Crossover Study

This clinical trial assesses differences in the delivery of THC to the bloodstream depending on whether nicotine vapes are used before or after THC. While there has been much recent publicity about vaping products and concern about their safety considering their increasing use for THC administration, the THC delivery profile associated with THC liquid vaping products in human subjects is currently unknown. Importantly, how the delivery to the bloodstream of THC vaping liquids compare to delivery from smoked cannabis, which is the most used method of cannabis delivery, will serve as an important benchmark for evaluating the delivery and effects of THC vaping products, and their relative safety.

Start Date15 Mar 2026

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

[+1]

100 Clinical Results associated with Nicotine

100 Translational Medicine associated with Nicotine

100 Patents (Medical) associated with Nicotine

35,057

Literatures (Medical) associated with Nicotine

01 May 2026·ADDICTIVE BEHAVIORS

Longitudinal trends in the past 30-day co-use of nicotine/tobacco, alcohol, and cannabis among youth and adults in the PATH study

Article

Author: Sokolovsky, Alexander W ; Murphy, Cara M ; Micalizzi, Lauren

INTRODUCTION:

The co-use of substances confers risks above single-product use and has significant public health implications. This study investigated trends in past 30-day co-use of nicotine/tobacco products with alcohol and cannabis in the US using Population Assessment of Tobacco and Health Study data from Waves 4-6 (December 2016-November 2021).

METHODS:

All wave 4-6 PATH participants age 15+ were included in analyses. Changes across wave in past 30-day co-use of cigarettes, e-cigarettes, and other tobacco products (OTP; cigars, filtered cigars, smokeless, hookah, snus, and cigarillo) with alcohol and cannabis, moderated by age (15-17,18-24, 25-34,35-64, 65+), and controlling for demographics were investigated.

RESULTS:

Changes in co-use of tobacco products with cannabis and alcohol varied across age and product. Cigarette and alcohol co-use was most prevalent across all adult ages, with rates declining over time among young adults (18-24, 25-34) but stable in older adults (65+). Rates of e-cigarette and alcohol co-use increased among young adults, possibly supplanting alcohol and cigarette co-use. E-cigarette and alcohol co-use was the most popular pattern of co-use in youth, with initially increasing and then declining prevalence. Co-use of e-cigarette and cannabis increased at Wave 5 among those 15-17, 18-24, and 25-34, although this increase lessened in all groups except those age 25-34 at Wave 6. Cigarette and cannabis co-use rates, and co-use rates of OTP with both cannabis and alcohol were generally stable or decreasing.

CONCLUSIONS:

Findings highlight the complex interplay between substance use patterns and developmental stages and the dynamic nature of co-use in ever-evolving tobacco and cannabis marketplaces.

01 May 2026·TALANTA

Chemical characterization and quantification of nicotine in e-liquids consumed in Brazil using DI-SPME–GC–MS

Article

Author: Souza E Souza, Laura Beatriz ; Brandão, João Pedro Cezário ; Valenzuela, Eduard F ; de Freitas Santos Júnior, Aníbal ; Simões, Ivana Ferreira

Electronic cigarettes and their refill liquids (e-liquids) have become increasingly popular, despite regulatory restrictions in Brazil. The lack of quality control raises concerns regarding the presence of harmful or undeclared substances. This study aimed to perform both target and untargeted analyses of marketed e-liquids in Brazil. A total of 20 samples were analyzed using direct immersion solid-phase microextraction coupled with gas chromatography-mass spectrometry (DI-SPME-GC-MS). The target analysis focused on nicotine quantification in SIM mode, while the untargeted analysis characterized volatile and semi-volatile organic compounds in full-scan mode. The untargeted screening identified approximately 673 compounds, including alcohols, esters, aldehydes, ketones, terpenes, and aromatic hydrocarbons. Toxic compounds such as benzaldehyde, ethyl maltol, benzophenone, myrcene, and 2,3-pentanedione were detected. Emerging contaminants including polycyclic aromatic hydrocarbons (PAHs), phthalates, and benzene derivatives compounds were also found in several samples, indicating contamination and potential health risks. The DI-SPME-GC-MS method was optimized through experimental design and validated, showing good linearity (R² = 0.9986), recovery (86-101 %), precision (RSD <3 %), and adequate quantification limit (LOQ = 0.053 mg L^-1). Nicotine concentrations ranged from 0.005 to 50.672 mg mL^-1 (5.11-50672.10 mg L^-1), with most samples showing discrepancies between labeled and measured values. Even samples labeled as "nicotine-free" contained detectable levels. These findings reveal significant inconsistencies in product labeling and the presence of hazardous compounds, highlighting the urgent need for regulatory oversight and toxicological evaluation of e-liquids consumed in Brazil.

01 May 2026·TOXICOLOGY

A comparative toxicological evaluation of nicotine and its analog 6-methyl nicotine in E-cigarette aerosol utilizing a 3D in vitro human respiratory model

Article

Author: Sengupta, Mohana ; Sun, Yehao ; Elzein, Atallah ; Faizan, Md Imam ; Raghu, Rhea ; Marczylo, Tim ; Effah, Felix ; Rahman, Irfan ; Kaur, Gagandeep ; Strongin, Robert M

Under the U.S. Tobacco Regulatory Act of 2020, all novel nicotine-containing products require a Premarket Tobacco Product Application (PMTA) and FDA authorization before they can be marketed. However, lengthy PMTA review timelines have prompted some manufacturers to replace traditional nicotine with 6-methyl-nicotine (6-MN), a non-tobacco-derived analog that delivers comparable psychoactive effects while evading existing regulatory pathways. Despite its growing market presence as a purportedly "safer" alternative, the toxico-pharmacokinetic profile of 6-MN remains poorly characterized. This study assessed the toxicity after exposure to nicotine or 6-MN-containing e-liquid aerosols using a 3D EpiAirway tissue model. RT-qPCR analyses revealed differential effects on transcripts associated with DNA damage (53BP1, ATR), inflammation (NF-κB1), and cancer (MYCBP). Morphological evaluation of the airway tissues exposed to either aerosol showed an increase in epithelial thickness, a decrease in E-cadherin protein levels, increased goblet cell hypertrophy, evidenced by positive PAS staining and elevated mucus (MUC5AC protein) production, and a reduction in Occludin protein (part of the tight junction complex), which is suggestive of epithelial remodeling. Exposure to PG/VG aerosols alone significantly increased the release of MIP-1α, IFN-γ, and IL-4. Conversely, spearmint-flavored aerosols containing 6-MN or nicotine decreased several pro-inflammatory cytokines, significantly reducing TNF-α, Eotaxin, MCP-1, RANTES, and G-CSF levels, potentially via NF-κB and ERK1/2 pathways. Our findings reveal differential toxicological and chemical profiles for nicotine and 6-MN aerosols; however, flavorings may confer similar cytotoxicity, as measured by LDH and metabolic activity, in 6-MN formulations as they do in those with nicotine. Thus, 6-MN is not a "safer" nicotine alternative.

215

News (Medical) associated with Nicotine

10 Feb 2026

·www.prnewswire.com

Qnovia's Inhaled Nicotine Replacement Therapy Delivers Positive Results in First Human Study

RespiRx ™ achieves cigarette-comparable nicotine delivery with favorable safety profile, marking first major advancement in smoking cessation in decades IRVINE, Calif., Feb. 10, 2026 /PRNewswire/ -- Qnovia, Inc., a pharmaceutical and medtech company revolutionizing inhaled therapeutics, today announced positive results from its Phase 1 clinical trial evaluating the safety and efficacy of RespiRx™, a handheld inhalable nicotine replacement therapy (NRT). With this milestone, Qnovia's ultraportable vibrating mesh nebulizer is poised to be the first safe and effective NRT innovation introduced to the market in over 20 years. The clinical trial was conducted in 2025 on 25 healthy adults and aimed to identify the pharmacokinetic profile of RespiRx™ in relation to cigarettes and Nicotrol Inhaler®, a buccal NRT whose production was discontinued in 2023. Key findings include: A lower plasma nicotine exposure than cigarettes, while maintaining effective craving relief without excessive dosing Delivers cigarette-like nicotine uptake, an essential factor for effective craving control and smoking cessation. Reaching peak blood levels in 7 minutes with just 10 puffs (Cmax 8.7 ng/mL), demonstrating a Tmax comparable to combustible cigarettes of ~6 minutes, significantly outperforming authorized legacy nicotine replacement therapies Meaningful reduction in urge-to-smoke scores, suggesting effective satiation No serious side effects or adverse events; only a moderate cough was reported The study employed a randomized, open-label, three-way crossover design for adult smokers. Participants received single doses of RespiRx™, a traditional cigarette and Nicotrol Inhaler® in a randomized fashion. This allowed researchers to effectively evaluate and compare peak nicotine levels (Cmax), nicotine exposure over time (Tmax), the rate at which nicotine reached the bloodstream (AUC), and participants' urge to smoke score. "We are very encouraged by the results of the first-in-human FDA trial of RespiRx™," said Mario Danek, founder and CEO of Qnovia. "The findings show that our novel nicotine delivery method — via a cool mist, without any heating or combustion — matches the speed and habit-loop of smoking and vaping without the carcinogens. As the first major NRT innovation in two decades, and first-ever truly inhaled Investigational New Drug-cleared NRT, RespiRx™ is uniquely positioned to globally drive towards a smoke-free generation and meaningfully reduce the burden of smoking-related disease." ‑ Smoking remains the world's leading cause of preventable death. The World Health Organization estimates about 8 million deaths annually among roughly 1.2 billion smokers across the globe. And yet, quit rates remain in the single digits, with most going "cold turkey." In fact, 70% of worldwide smokers want to quit, but relapse rates sit between 60% to 90% within the year. While several nicotine replacement therapies (patches, gums, lozenges, legacy devices, etc.) exist, they typically have low success rate due to slow onset, sensory mismatch and poor adherence. "Most current FDA-approved therapies were designed decades ago and fail to reflect the neurobiology, pharmacokinetics, and behavioral drivers of addiction," Danek added. "The consequence is staggering: smoking-related disease is projected to generate trillions of dollars in direct and indirect healthcare burden over the coming decade, spanning respiratory disease, cardiovascular morbidity, cancer, and premature mortality." Robert West, Chairman of Qnovia's Scientific Advisory Board, Professor Emeritus of Health Psychology at University College London, and one of the world's most influential behavioral scientists in smoking cessation commented: "From the very early days of development of nicotine replacement therapy to help smokers quit, the challenge was to find a way to give smokers the nicotine they crave in a way that eases their transition to becoming non-smokers. Medicinal nicotine products, such as skin patches and gum, have lacked the speed of nicotine delivery needed for many smokers, while, more recently, e-cigarettes, as mass-market products, have raised concerns about creating or sustaining nicotine addiction in people who would otherwise not have smoked. Qnovia's nicotine device offers the prospect of a medicinal nicotine product that is effective at controlling cigarette cravings and easing the transition to smoking cessation for millions of smokers." Qnovia's RespiRx™ platform represents a category-defining shift, engineered to deliver controlled, pharmaceutical-grade nicotine directly to the lung — without combustion, smoke, or carcinogens — while preserving the rapid onset and sensory cues that reinforce smoking behavior. By restoring pulmonary delivery and clinically relevant pharmacokinetics, RespiRx addresses the primary reasons conventional NRTs underperform in real-world settings. About Qnovia, Inc. Qnovia, Inc. is a pharmaceutical and medtech company focused on developing and commercializing proprietary inhalation device technologies to improve patient outcomes. The company's drug delivery platform, the RespiRx™, is the first cartridge-based, ultra-portable vibrating mesh nebulizer. Qnovia sees significant opportunity to utilize its drug delivery technologies to improve the treatment of several indication areas with several generic as well as select investigational new drugs. The company was founded by Mario Danek in 2018 to build cutting-edge drug delivery platforms that improve patient outcomes through superior device technologies. Learn more at . SOURCE Qnovia, Inc. 21% more press release views with Request a Demo

Clinical ResultPhase 1

07 Feb 2026

·www.drugs.com

Watching the Super Bowl? Doctors Warn About Hidden Health Risks for Fans

SATURDAY, Feb. 7, 2026 — Planning to watch the Super Bowl this weekend as the Seattle Seahawks face off against the New England Patriots ? Doctors say the big game can also bring big health risks, from heart strain to food poisoning and alcohol-related emergencies, especially for folks with underlying medical conditions. Experts from Rutgers New Jersey Medical School and the New Jersey Poison Control Center shared simple tips to help fans avoid emergencies before, during and after Sunday’s big game. Exciting events like a close football game can raise blood pressure and strain the heart and brain, studies suggest. People with heart disease, high blood pressure, diabetes, irregular heartbeats or narrowed arteries face higher risks. Experts suggest you: Take your medications as prescribed. Take your medications as prescribed. Avoid watching the game alone if you have heart problems. Avoid watching the game alone if you have heart problems. Keep rooms cool and comfortable. Keep rooms cool and comfortable. Don’t overeat. Don’t overeat. Drink alcohol in moderation, especially if you take heart or blood-thinning medication. Drink alcohol in moderation, especially if you take heart or blood-thinning medication. Watch for heart attack symptoms , including chest pressure or burning, pain in the arms or jaw, shortness of breath, nausea, sweating, dizziness or sudden stomach pain. Stroke warning signs include slurred speech, sudden weakness in the face or limbs, vision trouble, loss of balance or a severe headache. Call 911 right away if you notice any of these symptoms. Cold and flu season means many people are taking cough or allergy meds, and mixing these with alcohol can be dangerous. Some medications can also make driving unsafe by causing sleepiness, blurry vision or slower reactions. If you’re the one hosting, keep all medicines locked away and out of reach of kids and pets. If you’re sick, don’t cook for others. Doctors remind hosts to follow four basic food safety steps: clean, separate, cook and chill. That means: Wash hands and surfaces often. Wash hands and surfaces often. Keep raw meat and seafood away from other foods. Keep raw meat and seafood away from other foods. Use a thermometer to fully cook meals. Use a thermometer to fully cook meals. Refrigerate leftovers within two hours. Refrigerate leftovers within two hours. Food poisoning symptoms such as nausea, vomiting, stomach cramps, diarrhea and fever can start within just a few hours. Also be alert for food allergies. About 1 in 13 children in the U.S. has a food allergy, data shows, and reactions can be pretty severe. Keep an eye on furry friends, too. Chocolate, candy and foods with xylitol can poison pets and may cause vomiting, diarrhea and more. Many people underestimate how much alcohol they drink during parties. And today’s beers and mixed drinks often contain more alcohol than expected. Signs of alcohol poisoning include confusion, slow breathing, vomiting, seizures, blue skin or trouble waking up. “Sleeping it off” is not safe. Got a hangover? Experts say hydration matters the most. Edible cannabis, nicotine and vaping products can look appealing to children and pets. These products may contain high or unknown amounts of THC and can cause serious illness, even trouble breathing in young children. If someone is unconscious or showing signs of a heart attack or stroke, call 911. For poison concerns, call Poison Control at 800-222-1222 for free, 24/7 help. Sources Rutgers University-New Brunswick, news release, Jan. 31, 2020

AHA

03 Feb 2026

·www.sciencedaily.com

This unexpected plant discovery could change how drugs are made

Plants make chemical weapons to protect themselves, and many of these compounds have become vital to human medicine. Researchers found that one powerful plant chemical is produced using a gene that looks surprisingly bacterial. This suggests plants reuse microbial tools to invent new chemistry. The insight could help scientists discover new drugs and produce them more sustainably.Plants naturally produce chemicals called alkaloids to protect themselves from threats such as insects and disease. People have relied on these same compounds for generations, using them in pain relief, medical treatments, and everyday products including caffeine and nicotine. Scientists want to better understand how plants create alkaloids so they can develop medicines faster, at lower cost, and with less harm to the environment. A Powerful Plant Chemical With an Unexpected Origin Researchers at the University of York focused on a plant known as Flueggea suffruticosa, which makes a strong alkaloid called securinine. While studying how this compound is produced, the team uncovered a surprising detail. The key gene responsible for making securinine resembles genes typically found in bacteria rather than in plants. This finding suggests that plants may have adopted an unusual evolutionary strategy. Instead of relying only on traditional plant chemistry, they appear to reuse molecular tools commonly seen in microbes to build defensive chemicals. The researchers believe this approach may be more widespread across the plant kingdom than previously thought. Plants Reusing Microbial Tools Dr. Benjamin Lichman from the University of York's Department of Biology explained why the discovery stood out. "Plants and bacteria are really different forms of life, and so it really was a surprise to see that this significant plant chemical was being driven from a bacterial-like gene. "We think that this means plants 'recycle' biological tools that are more commonly found in microbes, when they can be useful to them. Even more interesting was that this gene makes securinine in a completely different way from other well-known plant chemicals." Once the researchers recognized this new chemical pathway, they began finding similar genes hidden within the DNA of many other plants. This gave scientists a powerful new method for identifying useful natural compounds and understanding how they are made. New Paths for Drug Production and Safety These plant genes could eventually be used to manufacture valuable chemicals in laboratory settings. Doing so would reduce the need to harvest rare plants or rely on environmentally damaging industrial processes. Dr. Lichman noted that alkaloids often need careful handling. "Alkaloids can be toxic, so when we use them in medicines they have to be highly controlled and often modified, so understanding the process that goes into making alkaloids can help us develop new methods for producing them in the lab or removing them to make some plants less toxic. "Now that we know how to look for this chemical production, and that we can find it in more plants than we originally thought, we have new avenues to explore for the production and discovery of safe drugs." Implications for Agriculture and the Environment The findings, published in the journal New Phytologist, may also deepen scientists' understanding of how plants grow and survive. This knowledge could eventually support the development of stronger and more resilient crops. Researchers say the study highlights how much remains to be learned from nature. Unexpected discoveries in basic plant science can lead to major advances in medicine, agriculture, and environmental sustainability.

100 Deals associated with Nicotine

External Link

KEGG	Wiki	ATC	Drug Bank
D03365	Nicotine	N07BA01	DB00184

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Smoking Cessation	South Korea	SAEHAN PHARM	28 Aug 2007
Tobacco Use Disorder	Australia	Johnson & Johnson Pacific Pty Ltd.	27 Nov 2001
Nicotine Dependence	United States	Haleon US Capital LLC	13 Jan 1984

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acral Lentiginous Malignant Melanoma	Phase 3	United States	McNeil AB	01 Mar 2011
Dyskinesia, Drug-Induced	Phase 2	United States	Neuraltus Pharmaceuticals, Inc.	01 Oct 2009
Parkinson Disease	Phase 2	United States	Neuraltus Pharmaceuticals, Inc.	01 Oct 2009
Lung Cancer	Phase 1	United States	Pfizer Inc.	16 Jun 2017
disorder of aging	Preclinical	China	The Shenzhen Institutes of Advanced Technology	07 Feb 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03652740 (CTgov)	Phase 1	-	25	Placebo+Nicotine+Methylphenidate (Caffeine Chooser)	ugzcqreokb(iaeuiajjwf) = mduegbvdei xskkxtyrwz (wpopbhpbjr, 1.20) View more	-	02 Feb 2026
				Placebo+Nicotine+Methylphenidate (Caffeine Non-Chooser)	ugzcqreokb(iaeuiajjwf) = tghlytbuui xskkxtyrwz (wpopbhpbjr, 0.60) View more
NCT04965181 (CTgov)	Not Applicable	Smoking	504	Mindfulness-Based Addiction Treatment+Nicotine Replacement Therapy (Mindfulness-based Addiction Treatment (MBAT) + iQuit Mindfully)	uosvflfnwo = lqofpzkzio hmkvascbah (wfdlsbkkej, faobhonfdg - kpctyphbud) View more	-	30 Dec 2025
				Self-help materials+Nicotine Replacement Therapy (iQuit Mindfully)	uosvflfnwo = sgaupssjuq hmkvascbah (wfdlsbkkej, ukmijdjuhx - jqiuwtofqz) View more
NCT06289192 (CTgov)	Phase 4	Lung Cancer \| Tobacco Use Disorder	5	Lung Cancer Screening+Nicotine Replacement Product	cecxuaqwmz = jolleuqslg pubbtfqqtn (bupqvhnylx, aubmvrcgik - kdmollxgxd) View more	-	10 Sep 2025
NCT04038255 (CTgov)	Phase 4	Neoplasms	20	Self-help smoking cessation materials+Nicoderm (Usual Care)	cfmbjdhsyy = buaqfhfsyi cdjflrxlkf (isetipcwoa, xvxffzxbey - cecacdpewz) View more	-	09 Sep 2025
				Craving-to-Quit app+Nicoderm (Craving-to-Quit App)	cfmbjdhsyy = rshlqkqdis cdjflrxlkf (isetipcwoa, aeezgyeagy - vskkgefuth) View more
NCT04590404 (CTgov)	Phase 3	Smoking	606	Metabolism Informed Smoking Treatment (Nicotine metabolite ratio (NMR)-based selection of pharmacotherapy)+Nicotine Replacement Therapy+Varenicline	pmikwtxdgu = gdhamocwfs scsixnbosz (cpyibgfvnu, rgmmnlqbuj - xyefwamkud) View more	-	05 Jun 2025
NCT05030766 (CTgov)	Phase 4	Smoking Cessation \| HIV Infections \| Smoking	95	Nicotine replacement patches (Mindfulness Training (MT) and NRT (Phase 1))	iuqsuwqsbw = ofpkhpzrqr pzmejqutns (pgcslukrfu, qbnatmxhcb - uscrhmjamq) View more	-	04 Jun 2025
				Nicotine replacement patches+NRT (Contingency Management (CM) and NRT (Phase 1))	iuqsuwqsbw = xluuxvchje pzmejqutns (pgcslukrfu, xuyawipuhf - juuiftmokw) View more
NCT04946825 (CTgov)	Phase 2	Smoking Cessation \| Nicotine Dependence	396	Nicotine replacement therapy patch+Continue electronic cigarettes (Quit Cigarettes, But Continue Using E-cigarettes, With Nicotine Replacement Therapy and Text Support)	mqqnsshgjj = ipkiybonsr whqcnlkymx (tfjonsziwd, wedefbmtbd - vgrrshpqre) View more	-	22 May 2025
				Nicotine replacement therapy patch+Quit electronic cigarettes (Quit Cigarettes and Quit E-cigarettes With Nicotine Replacement Therapy and Text Support.)	mqqnsshgjj = rfivkdqeyz whqcnlkymx (tfjonsziwd, ukpjallrlo - wcgzcwrpuv) View more
NCT02265874 (CTgov)	Phase 1/2	Sarcoidosis, Pulmonary	50	Habitrol (Treatment)	qhjtcmnozb(divxpaqwdc) = oelcumlgcs qblqkmlckr (djjcccfkwd, 0.22) View more	-	24 Apr 2025
				Placebo to Habitrol (Control)	qhjtcmnozb(divxpaqwdc) = daydavjjjz qblqkmlckr (djjcccfkwd, 0.04) View more
NCT04994444 (CTgov)	Phase 2/3	Smoking Cessation	49	Nicoderm CQ (Preloading)	thkezyhumy(kvywwwkumq) = lqrxmrxuhx cfqbgvxsza (rlyoyqkyzp, 13.2) View more	-	06 Apr 2025
				Nicoderm CQ (Standard Treatment)	thkezyhumy(kvywwwkumq) = xectnuymvv cfqbgvxsza (rlyoyqkyzp, 21.8) View more
NCT04433767 (Pubmed)	Phase 2	Depressive Disorder nicotine metabolite concentrations	29	Transdermal nicotine patches	mvtzipnjkt(gzmpqnpuii) = improvement in self-reported affective symptoms (apathy, insomnia, rumination, and generalized anxiety symptoms), negativity bias, and disability sddicfdgfb (wgzjxejeop ) View more	Positive	01 Oct 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis